DAWN Chief Commercial Officer reports RSU conversion and share sale
Rhea-AI Filing Summary
Day One Biopharmaceuticals (DAWN) reported insider equity activity by its Chief Commercial Officer on a Form 4. On 11/15/2025, several batches of Restricted Stock Units (RSUs) converted into a total of 10,536 shares of common stock through multiple transactions coded "M". Following these RSU settlements, the officer beneficially owned 54,535 shares of common stock directly.
On 11/17/2025, the officer sold 3,726 shares of common stock in a transaction coded "S" at a weighted average price of $8.9147 per share, as part of block trades executed in a price range from $8.545 to $9.305. The filing states that this sale was made solely to cover tax liabilities arising from the RSU settlements. The RSUs vest in quarterly installments over time, subject to continued service, and do not have an expiration date.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,726 | $8.9147 | $33K |
| Exercise | Restricted Stock Unit (RSU) | 3,162 | $0.00 | -- |
| Exercise | Restricted Stock Unit (RSU) | 3,687 | $0.00 | -- |
| Exercise | Restricted Stock Unit (RSU) | 3,687 | $0.00 | -- |
| Exercise | Common Stock | 3,162 | $0.00 | -- |
| Exercise | Common Stock | 3,687 | $0.00 | -- |
| Exercise | Common Stock | 3,687 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Includes 2,068 shares of Common Stock acquired by the Reporting Person on May 15, 2025 pursuant to the Issuer's employee stock purchase plan. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. The RSUs vested as to 1/4th of the total award on August 15, 2024, and the remaining 3/4 of the award vests in 12 substantially equal quarterly installments thereafter on November 15, February 15, May 15 and August 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. RSUs do not expire; they either vest or are canceled prior to the vesting date. The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
FAQ
What insider transaction did Day One Biopharmaceuticals (DAWN) report?
The Chief Commercial Officer of Day One Biopharmaceuticals (DAWN) reported RSU settlements into common stock on 11/15/2025 and a subsequent stock sale on 11/17/2025 on a Form 4.
How do the Day One Biopharmaceuticals RSUs vest for this officer?
One RSU grant vested 1/4 on August 15, 2024 with the remaining 3/4 vesting in 12 substantially equal quarterly installments, while another vests in 1/16 installments each quarter, all subject to continued service.